Release Date: 23-Jan-2025
Plamotamab (formerly known as XmAb 13676) is a bispecific antibody developed by Xencor, designed to target two key antigens involved in the immune response against hematological malignancies. It is currently being investigated for the treatment of various B-cell-related cancers, including chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma. Plamotamab is engineered using Xencor's proprietary XmAbandreg; technology, which incorporates specific modifications to the Fc portion of the antibody. This design aims to enhance the antibody’s specificity and tolerability compared to traditional therapies, offering a potentially more effective and safer treatment option for patients.
Download Report: https://www.kuickresearch.com/ccformF.php?t=1737625307
The bispecific nature of Plamotamab enables it to engage two distinct targets simultaneously. One binding site targets human CD3, a T-cell surface antigen, while the other binds to human CD20, a tumor-associated antigen that is primarily found on B-cells and frequently overexpressed in various B-cell malignancies. By binding to both T-cells and CD20-expressing tumor cells, Plamotamab facilitates the cross-linking of these cells, effectively stimulating a potent immune response. The result is the activation of cytotoxic T-lymphocytes (CTLs), which can then recognize and destroy the tumor cells expressing CD20. This mechanism of action enhances the body's immune system to target and eliminate cancerous cells more effectively.
Additionally, Plamotamab is designed with an Fc domain, which prolongs its half-life in the body and enhances its therapeutic effects. The Fc portion allows the antibody to bind to Fc receptors on immune cells, further enhancing T-cell-mediated tumor cell killing. This feature makes Plamotamab potentially more effective than other therapies that lack such prolonged immune engagement.
Plamotamab is currently undergoing Phase 2 clinical trials for the treatment of diffuse large B-cell lymphoma, and its unique mechanism of action offers hope for improved outcomes in patients with hematological malignancies that are difficult to treat with existing therapies.